Cargando…

A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion

Invariant Natural Killer T (iNKT) cells are a subset of T cells recognizing glycolipid antigens presented by CD1d. Human iNKT cells express a conserved T cell receptor (TCR)-α chain (Vα24-Jα18) paired with a specific beta chain, Vβ11. The cells are both innate-like, with rapid cytokine release, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheuplein, Felix, Thariath, Abraham, Macdonald, Susan, Truneh, Alemseged, Mashal, Robert, Schaub, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785425/
https://www.ncbi.nlm.nih.gov/pubmed/24086759
http://dx.doi.org/10.1371/journal.pone.0076692
_version_ 1782477655820468224
author Scheuplein, Felix
Thariath, Abraham
Macdonald, Susan
Truneh, Alemseged
Mashal, Robert
Schaub, Robert
author_facet Scheuplein, Felix
Thariath, Abraham
Macdonald, Susan
Truneh, Alemseged
Mashal, Robert
Schaub, Robert
author_sort Scheuplein, Felix
collection PubMed
description Invariant Natural Killer T (iNKT) cells are a subset of T cells recognizing glycolipid antigens presented by CD1d. Human iNKT cells express a conserved T cell receptor (TCR)-α chain (Vα24-Jα18) paired with a specific beta chain, Vβ11. The cells are both innate-like, with rapid cytokine release, and adaptive-like, including thymic positive selection. Over activation of iNKT cells can mediate tissue injury and inflammation in multiple organ systems and play a role in mediating the pathology associated with clinically important inflammatory diseases. At the same time, iNKT cell activation can play a role in protecting against infectious disease and cancer or modulate certain autoimmune diseases through its impact on both the innate and adaptive immune system. This suggests that approaches to cause iNKT cell reduction and/or depletion could treat inflammatory diseases while approaches to promote activation may have therapeutic potential in certain infections, cancer or autoimmune disease. This report summarizes the characterization of a humanized monoclonal depleting antibody (NKTT120) in the cynomolgus macaque. NKTT120 is being developed to treat iNKT mediated inflammation that is associated with chronic inflammatory conditions like sickle cell disease and asthma. NKTT120 binds to human iTCRs and to FCγRI and FCγRIII and has been shown to kill target cells in an ADCC assay at low concentrations consistent with the FCγR binding. iNKT cells were depleted within 24 hours in cynomolgus macaques, but T cell, B cell, and NK cell frequencies were unchanged. iNKT cell recovery was dose and time dependent. T cell dependent antigen responses were not impaired by NKTT120 mediated iNKT depletion as measured by response to KLH challenge. NKTT120 administration did not induce an inflammatory cytokine release at doses up to 10 mg/kg. These data support the use of NKTT120 as an intervention in inflammatory diseases where iNKT reduction or depletion could be beneficial.
format Online
Article
Text
id pubmed-3785425
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37854252013-10-01 A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion Scheuplein, Felix Thariath, Abraham Macdonald, Susan Truneh, Alemseged Mashal, Robert Schaub, Robert PLoS One Research Article Invariant Natural Killer T (iNKT) cells are a subset of T cells recognizing glycolipid antigens presented by CD1d. Human iNKT cells express a conserved T cell receptor (TCR)-α chain (Vα24-Jα18) paired with a specific beta chain, Vβ11. The cells are both innate-like, with rapid cytokine release, and adaptive-like, including thymic positive selection. Over activation of iNKT cells can mediate tissue injury and inflammation in multiple organ systems and play a role in mediating the pathology associated with clinically important inflammatory diseases. At the same time, iNKT cell activation can play a role in protecting against infectious disease and cancer or modulate certain autoimmune diseases through its impact on both the innate and adaptive immune system. This suggests that approaches to cause iNKT cell reduction and/or depletion could treat inflammatory diseases while approaches to promote activation may have therapeutic potential in certain infections, cancer or autoimmune disease. This report summarizes the characterization of a humanized monoclonal depleting antibody (NKTT120) in the cynomolgus macaque. NKTT120 is being developed to treat iNKT mediated inflammation that is associated with chronic inflammatory conditions like sickle cell disease and asthma. NKTT120 binds to human iTCRs and to FCγRI and FCγRIII and has been shown to kill target cells in an ADCC assay at low concentrations consistent with the FCγR binding. iNKT cells were depleted within 24 hours in cynomolgus macaques, but T cell, B cell, and NK cell frequencies were unchanged. iNKT cell recovery was dose and time dependent. T cell dependent antigen responses were not impaired by NKTT120 mediated iNKT depletion as measured by response to KLH challenge. NKTT120 administration did not induce an inflammatory cytokine release at doses up to 10 mg/kg. These data support the use of NKTT120 as an intervention in inflammatory diseases where iNKT reduction or depletion could be beneficial. Public Library of Science 2013-09-27 /pmc/articles/PMC3785425/ /pubmed/24086759 http://dx.doi.org/10.1371/journal.pone.0076692 Text en © 2013 Scheuplein et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Scheuplein, Felix
Thariath, Abraham
Macdonald, Susan
Truneh, Alemseged
Mashal, Robert
Schaub, Robert
A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion
title A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion
title_full A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion
title_fullStr A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion
title_full_unstemmed A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion
title_short A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion
title_sort humanized monoclonal antibody specific for invariant natural killer t (inkt) cells for in vivo depletion
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785425/
https://www.ncbi.nlm.nih.gov/pubmed/24086759
http://dx.doi.org/10.1371/journal.pone.0076692
work_keys_str_mv AT scheupleinfelix ahumanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT thariathabraham ahumanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT macdonaldsusan ahumanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT trunehalemseged ahumanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT mashalrobert ahumanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT schaubrobert ahumanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT scheupleinfelix humanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT thariathabraham humanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT macdonaldsusan humanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT trunehalemseged humanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT mashalrobert humanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion
AT schaubrobert humanizedmonoclonalantibodyspecificforinvariantnaturalkillertinktcellsforinvivodepletion